Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for PolyPid Ltd. (PYPD : NSDQ)

• Company Description    PolyPid Ltd. is a pharmaceutical company. It discovers, develops and commercializes antibiotic drugs for the prevention of surgical infections. The company's product candidate includes D-PLEX100, BONYPID-1000 and BONYPID-500 which are in clinical stage. PolyPid Ltd. is based in Petach Tikva, Israel. Number of Employees: 62

• Price / Volume Information    Yesterday's Closing Price: $5.02 Daily Weekly Monthly 20 Day Moving Average: 82,465 shares Shares Outstanding: 19.08 (millions) Market Capitalization: $95.80 (millions) Beta: 1.41 52 Week High: $5.12 52 Week Low: $2.44 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.19% 2.90% 12 Week 18.96% 9.97% Year To Date 15.67% 2.32%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 18 HASIVIM STREET - PETACH TIKVA,L3 495376 ISR ph: 972-74-719-5700 fax: - ir@polypid.com http://www.polypid.com

• General Corporate Information    Officers Dikla Czaczkes Akselbrad - Chief Executive Officer Brooke Story - Chairman Ori Warshavsky - Chief Operating Officer Jonny Missulawin - Chief Financial Officer Dalit Fellous Hazan - Executive Vice President Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: M8001Q126 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 19.08 Most Recent Split Date: 9.00 (0.03:1) Beta: 1.41 Market Capitalization: $95.80 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.31 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.34 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 10.91 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 50.00% vs. Previous Quarter: 14.63% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -241.96 12/31/25 - -291.42 09/30/25 - -313.65 ROA 03/31/26 - -126.91 12/31/25 - -131.82 09/30/25 - -128.32 Current Ratio 03/31/26 - 1.78 12/31/25 - 1.97 09/30/25 - 2.57 Quick Ratio 03/31/26 - 1.78 12/31/25 - 1.97 09/30/25 - 2.57 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.46 12/31/25 - 0.69 09/30/25 - 0.97 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©